MedTrace Logo

The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness

NCT07760896 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-08-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether a 30-day structured wellness program may support physical and emotional well-being in adults who are already taking a GLP-1 or dual GIP/GLP-1 medication for an FDA-approved indication. The study does not evaluate the GLP-1 medication itself or make changes to participants' medication treatment.

The main questions it aims to answer are:

1. Are there changes in participants' physical and emotional well-being after completing the 30-day wellness program?
2. Are there changes in areas such as mood, anxiety, functioning, mindfulness, self-compassion, eating-related behaviors, pain, and positive wellness?

Participants will:

1. Complete online questionnaires before and after the program.
2. Follow the WILD 5 Wellness program for 30 days, which includes daily practices related to exercise, mindfulness, sleep, social connection, and nutrition.
3. Complete a brief online tracking form each day during the 30-day program.

Conditions

  • Wellness

Interventions

BEHAVIORAL

WILD 5 Wellness Program

A 30-day structured wellness program that includes daily practices in five areas: exercise, mindfulness, sleep, social connection, and nutrition. Participants complete the wellness practices independently and complete daily online tracking during the 30-day program.

Sponsors & Collaborators

  • Saundra Jain

    lead OTHER

Principal Investigators

  • Saundra Jain, MA, PsyD, LPC · The University of Texas at Austin School of Nursing

  • Rakesh Jain, MD, MPH · Texas Tech University Health Sciences Center School of Medicine - Permian Basin

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-10-31
Completion
2027-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07760896 on ClinicalTrials.gov